Kv7.2 (KCNQ2) Protein

Migration, Crosslink

📖

Kv7.2 (KCNQ2) Protein

active

wiki page Created: 2026-04-02T07:19:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-kv7-2

📖 Wiki Page

protein848 wordssynced 2026-04-02

Kv7.2 (KCNQ2) Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Kv7.2 (KCNQ2) Protein</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Kv7.2 (KCNQ2)</td>
</tr>
<tr>
<td class="label">Gene Encoding</td>
<td>KCNQ2</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>O43526</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~100 kDa</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Axon initial segment, soma, dendrites</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Voltage-gated potassium channels (Kv7/KCNQ)</td>
</tr>
<tr>
<td class="label">Channel Stoichiometry</td>
<td>Tetramer (usually Kv7.2/7.3 heterotetramers)</td>
</tr>
</table>

Introduction

Kv7.2 (Kcnq2) Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Kv7.2 (KCNQ2) is a voltage-gated potassium channel that mediates the M-current, a slowly activating potassium current critical for neuronal excitability regulation. Kv7.2 channels stabilize the resting membrane potential and prevent excessive neuronal firing. Mutations in KCNQ2 cause neonatal seizures and epileptic encephalopathy. [@retigabine2012]

...

Kv7.2 (KCNQ2) Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Kv7.2 (KCNQ2) Protein</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Kv7.2 (KCNQ2)</td>
</tr>
<tr>
<td class="label">Gene Encoding</td>
<td>KCNQ2</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>O43526</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~100 kDa</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Axon initial segment, soma, dendrites</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Voltage-gated potassium channels (Kv7/KCNQ)</td>
</tr>
<tr>
<td class="label">Channel Stoichiometry</td>
<td>Tetramer (usually Kv7.2/7.3 heterotetramers)</td>
</tr>
</table>

Introduction

Kv7.2 (Kcnq2) Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Kv7.2 (KCNQ2) is a voltage-gated potassium channel that mediates the M-current, a slowly activating potassium current critical for neuronal excitability regulation. Kv7.2 channels stabilize the resting membrane potential and prevent excessive neuronal firing. Mutations in KCNQ2 cause neonatal seizures and epileptic encephalopathy. [@retigabine2012]

This protein is involved in:

M-current: Mediates slowly activating potassium current
Neuronal excitability: Stabilizes resting membrane potential
Seizure suppression: Prevents hyperexcitability
Disease associations: Benign familial neonatal seizures, epileptic encephalopathy, migraine

Kv7.2 (encoded by KCNQ2) is the founding member of the KCNQ (Kv7) family of voltage-gated potassium channels. Together with Kv7.3, it forms the neuronal M-current, a critical regulator of neuronal excitability.

Protein Overview

Structure

Kv7.2 contains six transmembrane segments:

S1-S4: Voltage-sensing domain (S4 carries positive charges)
S5-S6: Pore domain (selectivity filter: GYG)
S6: Gate region controlling opening/closing
N-terminus: Assembly domain
C-terminus: Calmodulin-binding domain, assembly domain

Heteromeric Assembly

Kv7.2/7.3: Primary native channel composition
Co-assembly required: For functional M-current
Calmodulin interaction: Essential for proper trafficking

Normal Function

M-Current Properties

Slow activation: Time constant ~100 ms
Slow deactivation: Time constant ~300 ms
Voltage range: Activates at -50 to -30 mV
Non-inactivating: Sustained current during depolarization

Physiological Roles

Neuronal excitability: Determines firing threshold and pattern
Subthreshold integration: Modulates response to EPSPs
Spike frequency adaptation: Controls firing rate
Axon initial segment: Regulates action potential initiation
Neuroprotection: Reduces excitotoxicity risk

Regulation

Neuronal activity: Activity-dependent modulation
Phosphorylation: PKC, PKA modulation
Ankyrin-G: Anchored at axon initial segment
Calmodulin: Ca2+-dependent regulation

Role in Disease

Benign Familial Neonatal Seizures (BFNS1)

Autosomal dominant: 50% chance of inheritance
Channel dysfunction: Dominant-negative effect
Benign prognosis: Seizures resolve by age 1-4
Normal development: Typically typical outcome

Early-Onset Epileptic Encephalopathies

De novo mutations: Cause severe phenotypes
Ohtahara syndrome: Early infantile epileptic encephalopathy
West syndrome: Infantile spasms
Spectrum: Variable severity based on mutation

Alzheimer's Disease

Therapeutic potential: M-current enhancers
Retigabine: FDA-approved anticonvulsant activates Kv7.2/7.3
Neuroprotection: Reduces [amyloid-beta](/proteins/amyloid-beta) toxicity
Cognitive effects: Being investigated

Neuropathic Pain

Peripheral hyperexcitability: GIRK-like effects
Drug target: Kv7 activators for pain relief

Therapeutic Targeting

Approved Drugs

Retigabine (Azilect): Kv7.2/7.3 activator (withdrawn from market)
Flupirtine: Kv7 activator, analgesic

Investigational

Kv7.2/7.3 agonists: For AD, neuropathic pain
Channel blockers: For seizure control
Gene therapy: Under development

Key Publications

M-current discovery and characterization (1980). Nature. PMID: 6255612(https://pubmed.ncbi.nlm.nih.gov/6255612/)

KCNQ2 mutations in neonatal seizures (2012). Brain. PMID: 22427328(https://pubmed.ncbi.nlm.nih.gov/22427328/)

Kv7 channels in neuropathic pain (2019). Nature Reviews Drug Discovery. PMID: 31110317(https://pubmed.ncbi.nlm.nih.gov/31110317/)

Kv7.2/7.3 in Alzheimer's disease (2021). Journal of Neuroscience. PMID: 33883218(https://pubmed.ncbi.nlm.nih.gov/33883218/)

External Links

[UniProt: Kv7.2](https://www.uniprot.org/uniprot/O43526)
[IUPHAR: Kv7 Channels](https://www.guidetopharmacology.org/GRID/FamilyIntroduction?familiar=&topfamily=Voltage-gated%20potassium%20channels&subfamily=Kv7%20%28KCNQ%29%20channels)
[PDB: Kv7 Structures](https://www.rcsb.org/search?searchTerm=kv7%20kcnq)

Background

The study of Kv7.2 (Kcnq2) Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Brain Atlas Resources

[Allen Human Brain Atlas - Gene Expression](https://human.brain-map.org/microarray/search/show?search_term=KCNQ2)
[BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/)

Molecular Mechanisms

Channel Structure

KCNQ2 encodes the voltage-gated potassium channel subunit
Forms homomers or heteromers with KCNQ3
M-channel regulates neuronal excitability

Neuronal Function

Controls resting membrane potential
Regulates action potential repolarization
Modulates neurotransmitter release

Therapeutic Targeting

Retigabine: FDA-approved M-channel opener (ezogabine)
Flupirtine: Analgesic with M-channel activating properties
Novel compounds: Under development for epilepsy and pain

Disease Mechanisms

Epilepsy

Loss-of-function mutations cause benign familial neonatal seizures
Reduced M-current leads to hyperexcitability
Target for anti-epileptic drugs

Neuroprotection

M-channel activation reduces excitotoxicity
Potential for AD and PD neuroprotection
Reduces calcium influx via NMDA receptors

Research Directions

Novel M-channel modulators for neurological disorders
Understanding KCNQ2 mutations in neonatal epilepsy
Therapeutic applications in excitotoxicity

External Links

[NCBI - KCNQ2](https://www.ncbi.nlm.nih.gov/gene/3785)
[UniProt - Kv7.2](https://www.uniprot.org/uniprot/O43525)

References

[Unknown, KCNQ2/3 potassium channels in neuronal excitability (2004) (2004)](https://pubmed.ncbi.nlm.nih.gov/15537883/)

[Unknown, Retigabine for KCNQ-related epilepsy (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22366792/)

📖 View canonical wiki page →

Related Entities

KV72

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-kv7-2
kg_node_id	KV72
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-bb56b9fc7ae3
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-kv7-2'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

45%

Debates

0

Incoming

9

Outgoing

10

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Kv7.2 (KCNQ2) Protein

Kv7.2 (KCNQ2) Protein

Kv7.2 (KCNQ2) Protein

Introduction

Overview

Kv7.2 (KCNQ2) Protein

Kv7.2 (KCNQ2) Protein

Introduction

Overview

Protein Overview

Structure

Heteromeric Assembly

Normal Function

M-Current Properties

Physiological Roles

Regulation

Role in Disease

Benign Familial Neonatal Seizures (BFNS1)

Early-Onset Epileptic Encephalopathies

Alzheimer's Disease

Neuropathic Pain

Therapeutic Targeting

Approved Drugs

Investigational

Key Publications

See Also

External Links

Background

Brain Atlas Resources

Molecular Mechanisms

Channel Structure

Neuronal Function

Therapeutic Targeting

Disease Mechanisms

Epilepsy

Neuroprotection

Research Directions

See Also

External Links

References

💬 Discussion